AtriCure, Inc. (NASDAQ:ATRC) Shares Purchased by Emerald Advisers LLC

Emerald Advisers LLC raised its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 389,836 shares of the medical device company's stock after buying an additional 38,421 shares during the quarter. Emerald Advisers LLC owned about 0.82% of AtriCure worth $10,931,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Champlain Investment Partners LLC boosted its position in shares of AtriCure by 27.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company's stock worth $81,556,000 after purchasing an additional 575,605 shares in the last quarter. First Light Asset Management LLC boosted its holdings in AtriCure by 42.1% in the second quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company's stock worth $44,736,000 after acquiring an additional 581,843 shares in the last quarter. Hood River Capital Management LLC purchased a new stake in shares of AtriCure during the second quarter worth about $40,422,000. Millennium Management LLC increased its holdings in shares of AtriCure by 132.5% during the second quarter. Millennium Management LLC now owns 952,765 shares of the medical device company's stock valued at $21,694,000 after acquiring an additional 543,023 shares in the last quarter. Finally, Fiera Capital Corp raised its position in shares of AtriCure by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 918,207 shares of the medical device company's stock valued at $20,908,000 after purchasing an additional 10,432 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ATRC has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of AtriCure from $30.00 to $40.00 and gave the stock an "overweight" rating in a research report on Wednesday. Piper Sandler cut their target price on AtriCure from $65.00 to $40.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 31st. UBS Group raised their target price on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday. StockNews.com raised AtriCure from a "sell" rating to a "hold" rating in a report on Saturday, September 14th. Finally, Oppenheimer lifted their target price on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.11.

AtriCure Stock Performance

ATRC stock traded up $0.33 during trading on Friday, hitting $33.51. 844,154 shares of the company traded hands, compared to its average volume of 616,657. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.00. The company has a market cap of $1.63 billion, a PE ratio of -40.37 and a beta of 1.40. The stock's 50-day simple moving average is $28.02 and its 200 day simple moving average is $24.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.93.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The firm had revenue of $115.91 million during the quarter, compared to analyst estimates of $112.23 million. During the same period in the previous year, the firm earned ($0.20) EPS. The business's quarterly revenue was up 17.9% on a year-over-year basis. On average, equities analysts expect that AtriCure, Inc. will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Maggie Yuen sold 3,500 shares of the company's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the transaction, the director now owns 8,970 shares of the company's stock, valued at approximately $215,907.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.20% of the company's stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.